Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain.
Animals
Benzopyrans
Benzylamines
Brain
/ diagnostic imaging
Citalopram
/ metabolism
Dorsal Raphe Nucleus
/ diagnostic imaging
Female
Macaca mulatta
Morpholines
Phenethylamines
Piperazines
Positron-Emission Tomography
Receptor, Serotonin, 5-HT1B
/ metabolism
Receptor, Serotonin, 5-HT2A
/ metabolism
Selective Serotonin Reuptake Inhibitors
/ metabolism
Vortioxetine
/ metabolism
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
21
03
2019
accepted:
11
06
2019
revised:
04
06
2019
pubmed:
20
6
2019
medline:
17
3
2020
entrez:
20
6
2019
Statut:
ppublish
Résumé
Vortioxetine is a multimodal antidepressant approved for treatment of major depressive disorder. Preclinical studies have demonstrated that the mechanism of action of vortioxetine might be different from selective serotonin reuptake inhibitors (SSRIs), including larger serotonin (5-HT) release and direct modulation of several 5-HT receptors. In the current positron emission tomography (PET) study, we evaluated the mechanism of action of vortioxetine by comparing its effect to the SSRI citalopram on the binding of [
Identifiants
pubmed: 31216565
doi: 10.1038/s41386-019-0442-4
pii: 10.1038/s41386-019-0442-4
pmc: PMC6784989
doi:
Substances chimiques
5-methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-morpholin-4-yl-phenyl)amide
0
Benzopyrans
0
Benzylamines
0
Cimbi-36
0
Morpholines
0
N,N-dimethyl-2-(2-amino-4-methylphenylthio)benzylamine
0
Phenethylamines
0
Piperazines
0
Receptor, Serotonin, 5-HT1B
0
Receptor, Serotonin, 5-HT2A
0
Serotonin Uptake Inhibitors
0
Citalopram
0DHU5B8D6V
Vortioxetine
3O2K1S3WQV
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1706-1713Références
Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382:1575–86.
doi: 10.1016/S0140-6736(13)61611-6
Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455:894–902.
doi: 10.1038/nature07455
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357–66.
doi: 10.1016/S0140-6736(17)32802-7
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term out- comes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17.
doi: 10.1176/ajp.2006.163.11.1905
Garnock-Jones KP. Vortioxetine: A review of its use in major depressive disorder. CNS drugs. 2014;28:855–74.
doi: 10.1007/s40263-014-0195-x
Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharm Ther. 2015;145:43–7.
doi: 10.1016/j.pharmthera.2014.07.001
Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54:3206–21.
doi: 10.1021/jm101459g
Westrich L, Pehrson A, Zhong H, Nielsen SM, Frederiksen K, Stensbol TB, et al. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract. 2012;16:47 (Informa healthcare telephone house, 69–77 paul street, London EC2A 4LQ, England, 2012).
Mørk A, Pehrson A, Tottrup Brennum L, Moller Nielsen S, Zhong H, Lassen AB, et al. Pharmacological effects of Lu AA21004: A novel multimodal compound for the treatment of major depressive disorder. J Pharm Exp Ther. 2012;340:666–75.
doi: 10.1124/jpet.111.189068
Pehrson AL, Cremers T, Bétry C, van der Hart MGC, Jørgensen L, Madsen M, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol. 2013;23:133–45.
doi: 10.1016/j.euroneuro.2012.04.006
du Jardin KG, Jensen JB, Sanchez C, Pehrson AL. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol. 2014;24:160–71.
doi: 10.1016/j.euroneuro.2013.07.001
Lundberg J, Christophersen JS, Petersen KB, Loft H, Halldin C, Farde L. PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. Int J Neuropsychopharmacol. 2007;10:777–85.
doi: 10.1017/S1461145706007486
Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826–35.
doi: 10.1176/appi.ajp.161.5.826
Lundberg J, Tiger M, Landén M, Halldin C, Farde L. Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15:1167–72.
doi: 10.1017/S1461145711001945
Areberg J, Luntang-Jensen M, Søgaard B, Nilausen D. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharm Toxicol. 2012;110:401–4.
doi: 10.1111/j.1742-7843.2011.00810.x
Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol. 2013;23:1190–8.
doi: 10.1016/j.euroneuro.2013.01.002
Lee C-M, Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharm Sci. 2006;27:310–6.
doi: 10.1016/j.tips.2006.04.004
Nord M, Finnema SJ, Halldin C, Farde L. Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. Int J Neuropsychopharmacol. 2013;16:1577–86.
doi: 10.1017/S1461145712001617
Invernizzi R, Belli S, Samanin R. Citalopram’s ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug’s effect in the frontal cortex. Brain Res. 1992;584:322–4.
doi: 10.1016/0006-8993(92)90914-U
Gartside SE, Umbers V, Hajos M, Sharp T. Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharm. 1995;115:1064–70.
doi: 10.1111/j.1476-5381.1995.tb15919.x
Yang K-C, Stepanov V, Martinsson S, Ettrup A, Takano A, Knudsen GM, et al. Fenfluramine reduces [11C]Cimbi-36 binding to the 5-HT2A receptor in the nonhuman primate brain. Int J Neuropsychopharmacol. 2017;20:683–91.
doi: 10.1093/ijnp/pyx051
Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, Rivet J-M, Auclair A, et al. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharm Exp Ther. 2001;298:565–80.
Wong D, Threlkeld P, Robertson D. Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology. 1991;5:43–7.
pubmed: 1930610
Sánchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol. 1999;19:467–89.
doi: 10.1023/A:1006986824213
Council NR. Guide for the care and use of laboratory animals. 8th ed. Washington, DC: The National Academies Press; 2011.
Halldin C, Lundberg J, Sóvágó J, Gulyás B, Guilloteau D, Vercouillie J, et al. [11C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET. Synap (New Y, NY) 2005;58:173–83.
doi: 10.1002/syn.20189
Andersson JD, Pierson ME, Finnema SJ, Gulyás B, Heys R, Elmore CS, et al. Development of a PET radioligand for the central 5-HT1B receptor: Radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds. Nucl Med Biol. 2011;38:261–72.
doi: 10.1016/j.nucmedbio.2010.08.006
Ettrup A, Hansen M, Santini MA, Paine J, Gillings N, Palner M, et al. Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers. Eur J Nucl Med Mol Imaging. 2011;38:681–93.
doi: 10.1007/s00259-010-1686-8
Finnema SJ, Halldin C, Bang-Andersen B, Bundgaard C, Farde L. Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET study. Psychopharmacol (Berl) 2015;232:4159–67.
doi: 10.1007/s00213-015-3961-7
Varrone A, Sjoholm N, Eriksson L, Gulyás B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging. 2009;36:1639–50.
doi: 10.1007/s00259-009-1156-3
Rohlfing T, Kroenke CD, Sullivan EV, Dubach MF, Bowden DM, Grant Ka, et al. The INIA19 template and NeuroMaps atlas for primate brain image parcellation and spatial normalization. Front Neuroinform. 2012;6:27.
doi: 10.3389/fninf.2012.00027
Kranz GS, Hahn A, Savli M, Lanzenberger R. Challenges in the differentiation of midbrain raphe nuclei in neuroimaging research. Proc Natl Acad Sci USA. 2012;109:E2000.
doi: 10.1073/pnas.1206247109
Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. NeuroImage. 1996;4:153–8.
doi: 10.1006/nimg.1996.0066
Lundberg J, Odano I, Olsson H, Halldin C, Farde L. Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. J Nucl Med. 2005;46:1505–15.
pubmed: 16157534
Varnäs K, Nyberg S, Halldin C, Varrone A, Takano A, Karlsson P, et al. Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. J Cereb Blood Flow Metab. 2011;31:113–23.
doi: 10.1038/jcbfm.2010.55
Finnema SJ, Stepanov V, Ettrup A, Nakao R, Amini N, Svedberg M, et al. Characterization of [11C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain. NeuroImage. 2014;84:342–53.
doi: 10.1016/j.neuroimage.2013.08.035
Ettrup A, da Cunha-Bang S, McMahon B, Lehel S, Dyssegaard A, Skibsted AW, et al. Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36. J Cereb Blood Flow Metab. 2014;34:1188–96.
doi: 10.1038/jcbfm.2014.68
Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab. 2002;22:1440–52.
doi: 10.1097/01.WCB.0000033967.83623.34
Farde L, Wiesel F-A, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988;45:71–6.
doi: 10.1001/archpsyc.1988.01800250087012
Takano A, Halldin C, Farde L. SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: A PET study. Psychopharmacol (Berl) 2013;226:147–53.
doi: 10.1007/s00213-012-2901-z
Areberg J, Søgaard B, Hojer AM. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharm Toxicol. 2012;111:198–205.
Selvaraj S, Turkheimer F, Rosso L, Faulkner P, Mouchlianitis E, Roiser JP, et al. Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study. Mol Psychiatry. 2012;17:1254–60.
doi: 10.1038/mp.2012.78
Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram–a review of pharmacological and clinical effects. J Psychiatry Neurosci. 2000;25:241–54.
pubmed: 10863884
pmcid: 1407724
Sari Y. Serotonin1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev. 2004;28:565–82.
doi: 10.1016/j.neubiorev.2004.08.008
Ruf BM, Bhagwagar Z. The 5-HT1B receptor: a novel target for the pathophysiology of depression. Curr Drug Targets. 2009;10:1118–38.
doi: 10.2174/138945009789735192
Tiger M, Varnäs K, Okubo Y, Lundberg J. The 5-HT1B receptor-a potential target for antidepressant treatment. Psychopharmacol (Berl) 2018;235:1317–34.
doi: 10.1007/s00213-018-4872-1
Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, Yacoubi ME, et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Sci (New Y, NY). 2006;311:77–80.
doi: 10.1126/science.1117571
Nautiyal KM, Tritschler L, Ahmari SE, David DJ, Gardier AM, Hen R. A lack of serotonin 1B autoreceptors results in decreased anxiety and depression-related behaviors. Neuropsychopharmacology. 2016;41:2941–50.
doi: 10.1038/npp.2016.109
Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSE. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015;40:2025.
doi: 10.1038/npp.2015.52
McIntyre R, Harrison J, Loft H, Jacobson W, Olsen C. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016;19:pii: pyw055.
doi: 10.1093/ijnp/pyw055
El Mansari M, Lecours M, Blier P. Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Psychopharmacol (Berl) 2015;232:2343–52.
doi: 10.1007/s00213-015-3870-9
Finnema SJ, Scheinin M, Shahid M, Lehto J, Borroni E, Bang-Andersen B, et al. Application of cross-species PET imaging to assess neurotransmitter release in brain. Psychopharmacology. 2015;232:4129–57.
doi: 10.1007/s00213-015-3938-6
Yang K-C, Takano A, Halldin C, Farde L, Finnema SJ. Serotonin concentration enhancers at clinically relevant doses reduce [11C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain. Transl Psychiatry. 2018;8:132.
doi: 10.1038/s41398-018-0178-7
Dawson LA, Hughes ZA, Starr KR, Storey JD, Bettelini L, Bacchi F, et al. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): In vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity. Neuropharmacology. 2006;50:975–83.
doi: 10.1016/j.neuropharm.2006.01.010
Hudzik T, Smolka J, Litwin L, Porrey T, Pierson E. In vivo pharmacology of AZD1134, a novel 5-HT1B antagonist. Eur Neuropsychopharmacol. 2003;13:S181–2.
doi: 10.1016/S0924-977X(03)91727-5
Hudzik TJ, Yanek M, Porrey T, Evenden J, Paronis C, Mastrangelo M, et al. Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxytryptamine1B antagonist. J Pharm Exp Ther. 2003;304:1072–84.
doi: 10.1124/jpet.102.045468
Yamanaka H, Yokoyama C, Mizuma H, Kurai S, Finnema SJ, Halldin C, et al. A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques. Transl Psychiatry. 2014;4:e342.
doi: 10.1038/tp.2013.112
Jans LAW, Riedel WJ, Markus CR, Blokland A. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Mol Psychiatry. 2006;12:522.
doi: 10.1038/sj.mp.4001920
Veldman ER, Svedberg MM, Svenningsson P, Lundberg J. Distribution and levels of 5-HT 1B receptors in anterior cingulate cortex of patients with bipolar disorder, major depressive disorder and schizophrenia–An autoradiography study. Eur Neuropsychopharmacol. 2017;27:504–14.
doi: 10.1016/j.euroneuro.2017.02.011